HEXVIX

This brand name is authorized in Austria, Estonia, Spain, Finland, France, Ireland, Lithuania, New Zealand, Poland, United Kingdom

Active ingredients

The drug HEXVIX contains one active pharmaceutical ingredient (API):

1 Hexaminolevulinate UNII D4F329SL1O - HEXAMINOLEVULINATE HYDROCHLORIDE

Hexaminolevulinate blue light fluorescence cystoscopy is indicated as adjunct to standard white light cystoscopy to contribute to the diagnosis and management of bladder cancer in patients with known or high suspicion of bladder cancer. Read about Hexaminolevulinate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HEXVIX Powder and solvent for intravesical solution	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V04CX	Other diagnostic agents	V Various → V04 Diagnostic agents → V04C Other diagnostic agents
Discover more medicines within V04CX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1165902
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 66925
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 373205
Country: FR	Base de données publique des médicaments	Identifier(s): 61196720
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 113900
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1080949
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 18731
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100147527